Neuroone Medical Financials

NMTC Stock  USD 1.04  0.02  1.96%   
Neuroone Medical Technologies may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At present, Neuroone Medical's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Short and Long Term Debt Total is expected to grow to about 400.8 K, whereas Net Debt is forecasted to decline to (1.1 M). Key indicators impacting Neuroone Medical's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio0.00820.0086
Notably Down
Slightly volatile
The essential information of the day-to-day investment outlook for Neuroone Medical includes many different criteria found on its balance sheet. An individual investor should monitor Neuroone Medical's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Neuroone Medical.

Net Income

(10.53 Million)

  
Please note, the presentation of Neuroone Medical's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Neuroone Medical's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Neuroone Medical's management manipulating its earnings.

Neuroone Medical Stock Summary

Neuroone Medical competes with BioSig Technologies,, Biomerica, Beyond Air, Movano, and SANUWAVE Health. NeuroOne Medical Technologies Corporation operates as a medical technology company. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator for use with NeuroOnes combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. Neuroone Medical operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 11 people.
Specialization
Health Care, Health Care Equipment & Services
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS64130M2098
CUSIP64130M209 64130M100 686211103
LocationMinnesota; U.S.A
Business Address7599 Anagram Drive,
SectorHealth Care Equipment & Supplies
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.n1mtc.com
Phone952 426 1383
CurrencyUSD - US Dollar

Neuroone Medical Key Financial Ratios

Neuroone Medical Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets7.9M12.8M8.1M5.4M6.2M6.5M
Other Current Liab531.5K632.5K978.4K1.1M1.3M1.4M
Net Debt(6.6M)(8.0M)(5.1M)(1.2M)(1.1M)(1.1M)
Retained Earnings(40.8M)(50.8M)(62.7M)(75.0M)(67.5M)(64.1M)
Cash6.9M8.2M5.3M1.5M1.7M2.0M
Total Liab1.4M3.2M1.8M4.5M5.2M5.5M
Total Current Assets7.3M12.2M7.3M4.6M5.3M2.7M
Common Stock12.0K16.2K23.9K30.8K35.4K37.2K
Short Term Debt112.8K83.3K129.1K65.8K75.6K71.9K
Accounts Payable528.8K927.7K685.1K1.0M1.2M1.2M
Net Tangible Assets(1.4M)1.9M6.4M9.5M10.9M11.5M
Inventory98.3K704.5K1.7M2.6M3.0M3.2M
Other Current Assets244.0K296.6K263.7K359.1K413.0K433.6K
Intangible Assets134.2K111.9K89.6K67.3K60.5K113.3K
Net Invested Capital6.6M9.6M6.2M822.0K945.3K898.0K
Net Working Capital6.1M9.1M5.5M2.4M2.8M2.2M
Capital Stock35.8K16.2K23.9K30.8K35.4K23.9K

Neuroone Medical Key Income Statement Accounts

202020212022202320242025 (projected)
Interest Expense7.5M3.1K31.2K229.0K263.3K250.2K
Total Revenue178.1K171.2K2.0M3.5M4.0M4.2M
Gross Profit(97.7K)(70.8K)456.5K1.1M1.2M1.3M
Operating Income(10.2M)(10.0M)(12.0M)(11.9M)(10.7M)(10.2M)
Ebit(9.9M)(10.1M)(12.0M)(12.1M)(10.9M)(10.3M)
Ebitda(9.8M)(9.9M)(11.8M)(11.8M)(10.7M)(10.1M)
Income Before Tax(9.9M)(10.0M)(11.9M)(12.3M)(11.1M)(10.5M)
Net Income(9.9M)(10.0M)(11.9M)(12.3M)(11.1M)(10.5M)
Cost Of Revenue275.9K242.0K1.5M2.4M2.7M2.9M
Research Development3.9M4.9M6.9M5.1M5.8M2.9M
Income Tax Expense7.5M274.2K(109.9K)31.4K36.1K34.3K
Net Interest Income(7.5M)(3.1K)0.0(229.0K)(263.3K)(276.5K)

Neuroone Medical Key Cash Accounts

202020212022202320242025 (projected)
Change In Cash2.9M1.3M(2.8M)(3.9M)(3.5M)(3.3M)
Free Cash Flow(8.7M)(7.8M)(13.3M)(11.1M)(10.0M)(9.5M)
Other Non Cash Items69.4K212.2K96.4K(285.0K)(327.7K)(311.4K)
Capital Expenditures67.1K275.2K384.1K120.2K138.2K91.7K
End Period Cash Flow6.9M8.2M5.3M1.5M1.7M1.8M
Net Income(9.9M)(10.0M)(11.9M)(12.3M)(11.1M)(10.5M)
Investments(67.1K)(3.2M)2.6M(120.2K)(138.2K)(145.1K)
Depreciation80.7K118.6K199.3K246.8K283.8K298K
Change To Netincome1.2M8.7M1.8M1.1M1.3M2.2M

Neuroone Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Neuroone Medical's current stock value. Our valuation model uses many indicators to compare Neuroone Medical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Neuroone Medical competition to find correlations between indicators driving Neuroone Medical's intrinsic value. More Info.
Neuroone Medical Technologies is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Neuroone Medical's Return On Equity is projected to drop based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Neuroone Medical's earnings, one of the primary drivers of an investment's value.

Neuroone Medical Tec Systematic Risk

Neuroone Medical's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Neuroone Medical volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Neuroone Medical Tec correlated with the market. If Beta is less than 0 Neuroone Medical generally moves in the opposite direction as compared to the market. If Neuroone Medical Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Neuroone Medical Tec is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Neuroone Medical is generally in the same direction as the market. If Beta > 1 Neuroone Medical moves generally in the same direction as, but more than the movement of the benchmark.

Neuroone Medical Thematic Clasifications

Neuroone Medical Technologies is part of Medical Equipment investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Medical Equipment industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
Medical EquipmentView
This theme covers USA Equities from Medical Equipment industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in Neuroone Medical Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Neuroone Medical's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Neuroone Medical growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(6.22E-4)

At present, Neuroone Medical's Price Earnings To Growth Ratio is projected to slightly decrease based on the last few years of reporting.

Neuroone Medical January 23, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Neuroone Medical help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Neuroone Medical Technologies. We use our internally-developed statistical techniques to arrive at the intrinsic value of Neuroone Medical Technologies based on widely used predictive technical indicators. In general, we focus on analyzing Neuroone Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Neuroone Medical's daily price indicators and compare them against related drivers.

Complementary Tools for Neuroone Stock analysis

When running Neuroone Medical's price analysis, check to measure Neuroone Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuroone Medical is operating at the current time. Most of Neuroone Medical's value examination focuses on studying past and present price action to predict the probability of Neuroone Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuroone Medical's price. Additionally, you may evaluate how the addition of Neuroone Medical to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments